Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect

被引：48
|
作者：
Stader, Felix [1 ,2 ,3 ]
Khoo, Saye [4 ]
Stoeckle, Marcel [1 ,2 ,3 ]
Back, David [4 ]
Hirsch, Hans H. [1 ,2 ,5 ]
Battegay, Manuel [1 ,2 ,3 ]
Marzolini, Catia [1 ,2 ,3 ,4 ]
机构：
[1] Univ Hosp Basel, Div Infect Dis & Hosp Epidemiol, Dept Med, Basel, Switzerland
[2] Univ Hosp Basel, Div Infect Dis & Hosp Epidemiol, Dept Clin Res, Basel, Switzerland
[3] Univ Basel, Basel, Switzerland
[4] Univ Liverpool, Inst Translat Med, Dept Mol & Clin Pharmacol, Liverpool, Merseyside, England
[5] Univ Basel, Dept Biomed, Transplantat & Clin Virol, Basel, Switzerland
来源：
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2020年 / 75卷 / 10期
关键词：
ENZYMES; CYP1A2; CYP3A4;
D O I：
10.1093/jac/dkaa253
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
下载
收藏
页码：3084 / 3086
页数：3
相关论文
共 50 条
  • [31] Data on compounding lopinavir and ritonavir suspension for non-cooperative COVID-19 patients
    Zanon, D.
    Musazzi, U. M.
    Manca, A.
    Nicolo, A. De
    D'Avolio, A.
    Cilurzo, F.
    Maximova, N.
    Tomasello, C.
    Clementi, E.
    Minghetti, P.
    DATA IN BRIEF, 2020, 33
  • [32] Prediction of lopinavir/ritonavir effectiveness in COVID-19 patients: a recall of basic pharmacology concepts
    Dario Cattaneo
    Mario Corbellino
    Cristina Gervasoni
    European Journal of Clinical Pharmacology, 2021, 77 : 791 - 792
  • [33] Consultation psychiatry in COVID-19 patients: Lopinavir/ritonavir interactions with main psychiatric drugs
    Marcatili, Matteo
    Stefana, Alberto
    Colmegna, Fabrizia
    di Giacomo, Ester
    D'Amico, Emiliano
    Capuzzi, Enrico
    Dakanalis, Antonios
    Clerici, Massimo
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2021, 75 (04) : 145 - 146
  • [34] Acute Kidney Injury Associated With Lopinavir/Ritonavir Combined Therapy in Patients With COVID-19
    Binois, Yannick
    Hachad, Hafsah
    Salem, Joe-Elie
    Charpentier, Julien
    Lebrun-Vignes, Benedicte
    Pene, Frederic
    Cariou, Alain
    Chiche, Jean-Daniel
    Mira, Jean-Paul
    Nguyen, Lee S.
    KIDNEY INTERNATIONAL REPORTS, 2020, 5 (10): : 1787 - 1790
  • [35] Prediction of lopinavir/ritonavir effectiveness in COVID-19 patients: a recall of basic pharmacology concepts
    Cattaneo, Dario
    Corbellino, Mario
    Gervasoni, Cristina
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 77 (05) : 791 - 792
  • [36] Therapy with lopinavir/ritonavir and hydroxychloroquine is associated with acute kidney injury in COVID-19 patients
    Schneider, Johanna
    Jaenigen, Bernd
    Wagner, Dirk
    Rieg, Siegbert
    Hornuss, Daniel
    Biever, Paul M.
    Kern, Winfried V.
    Walz, Gerd
    PLOS ONE, 2021, 16 (05):
  • [37] Safety and effectiveness concerns of lopinavir/ritonavir in COVID-19 affected patients: a retrospective series
    Lepage, Marc-Antoine
    Rozza, Nicholas
    Kremer, Richard
    Grunbaum, Ami
    CLINICAL TOXICOLOGY, 2021, 59 (07) : 644 - 647
  • [38] Lopinavir-ritonavir versus darunavir-norvir for hospitalized COVID-19 patients
    Paroczai, Dora
    Bikov, Andras
    Blidaru, Andreea
    Bobu, Emanuel
    Cerbu, Bianca
    Marincu, Iosif
    Mihaicuta, Stefan
    Frent, Stefan
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [39] Efficacy and Safety of Atazanavir/Ritonavir Versus Lopinavir/Ritonavir in Hospitalized COVID-19 Patients: A Randomized Clinical Trial
    Siami, Zeinab
    Dehghan, Danial
    Khavandegar, Armin
    Lak, Mehran
    Bakhtiyari, Mahmood
    IRANIAN RED CRESCENT MEDICAL JOURNAL, 2022, 24 (05)
  • [40] Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID-19 patients
    Kalantari, Saeed
    Fard, Soheil R.
    Maleki, Donya
    Taher, Mahshid T.
    Yassin, Zeynab
    Alimohamadi, Yousef
    Minaeian, Sara
    JOURNAL OF MEDICAL VIROLOGY, 2021, 93 (12) : 6557 - 6565
12345